stockportfolio.pro
Stocks / PTGX vs SYRE
PTGX vs SYRE
Protagonist Therapeutics, Inc. and Spyre Therapeutics, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Protagonist Therapeutics, Inc. (PTGX) | Spyre Therapeutics, Inc. (SYRE) | |
|---|---|---|
| Market cap | $6.9B | $6.8B |
| Revenue (latest FY) | $46.02M | $0 |
| Net income (latest FY) | $-130.15M | $-155.20M |
| Revenue growth (5y CAGR) | 10.0% | — |
| Net margin | -282.8% | — |
| Return on equity | -21.2% | -21.7% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 1 | 0 |
| Positive free cash flow | Yes | — |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open PTGX — free Open SYRE — freeFrequently asked questions
Which is bigger, PTGX or SYRE?
Protagonist Therapeutics, Inc. is larger by market capitalization — $6.9B versus $6.8B.
Which grows faster, PTGX or SYRE?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.